Nutriband Inc NTRB

Health CareHealthcare Equipment & SuppliesUnited States of America

Last close 6.41 USD on Nov 2, 2026, +41.2% year to date

Quant rating

Quant rating D Rank 485 of 565 in Health Care

Growth D 429 of 565
Valuation B 183 of 565
Quality D 462 of 565
Revisions D 548 of 565
Momentum B 166 of 565

Wall Street consensus Buy (2.00)Average target 15.00 USD +134.0%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 78M
Enterprise value: 75M
52-week range: 2.80 – 9.14
3-year range: 2.05 – 10.72
Dividend yield: –
Beta (5 years): 2.14
Shares outstanding: 12.2M
Next earnings: –

About the company

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Growth and profitability

Growth and profitability by fiscal year
	2026	2025	2024	2023	2022	5Y avg
Revenue (mil)	2.0	2.1	2.1	2.1	1.4	–
Revenue growth	−4.8%	2.6%	0.3%	46.2%	50.7%	16.6%
EPS (basic, normalized)	−2.58	−0.99	–	−0.53	−0.81	–
EPS growth	–	–	–	–	–	–
Gross margin	27.8%	34.7%	41.3%	36.1%	35.5%	35.1%
Net margin	−1,475.2%	−489.9%	−263.0%	−215.6%	−448.1%	−578.4%
ROE	−125.6%	−162.9%	−73.1%	−43.9%	−65.1%	−94.1%

Balance sheet, last quarter
Cash & short-term investments (mil)	3.4
Current ratio	4.21x
Long-term debt (mil)	0
Net debt (mil)	−3.3
Total equity (mil)	5.3
Net debt / equity	−0.61x
Net debt / EBITDA	–

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2026 actual	2.0	−4.8%	36.7x	–	–	–	−2.58	−160.7%	−2.5x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2027	–	–	–	–	–	–	–	–
2028	–	–	–	–	–	–	–	–
2029	–	–	–	–	–	–	–	–

Earnings surprises EPS beat in 3 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	FQ-9	FQ-8	FQ-7	FQ-6	FQ-5	Jan 2025	Apr 2025	Jul 2025	Oct 2025	Jan 2026
Sales reported (mil)	–	–	–	–	–	0.6	0.7	0.6	0.3	0.4
Sales mean (mil)	–	–	–	–	–	0.7	0.7	0.7	0.7	0.8
Surprise	–	–	–	–	–	−9.4%	+0.4%	−11.8%	−48.7%	−47.6%
EPS reported	–	–	–	–	–	−0.51	−0.12	−0.18	−0.32	−0.08
EPS mean	–	–	–	–	–	−0.12	−0.16	−0.17	−2.13	−1.89
Surprise	–	–	–	–	–	−325.0%	+25.0%	−5.9%	+85.0%	+95.8%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
NTRB Nutriband Inc	78M	–	−1,475.2%	14.62x	–	–	–	–
LFMD LifeMD Inc	111M	−1.65x	−6.9%	13.87x	−4.5x	−25.3x	−21.1x	3.7x
APYX Apyx Medical Inc	110M	−2.15x	−21.2%	10.27x	−9.7x	−10.3x	−34.4x	−41.7x
VANI Vivani Medical Inc	98M	–	–	5.14x	−3.4x	−2.8x	–	–
CBUS Cibus Inc	95M	−2.55x	−3,492.3%	6.41x	−1.2x	−1.5x	−6.6x	−6.9x
STXS Stereotaxis Inc	88M	0.28x	−70.8%	4.93x	−4.3x	−6.0x	−37.7x	−27.6x
Mean		−1.52x	−1,013.3%	9.21x	−4.6x	−9.2x	−24.9x	−18.1x
Median		−1.90x	−70.8%	8.34x	−4.3x	−6.0x	−27.7x	−17.3x

Technical analysis

1M−12.0%
3M+124.9%
1Y−4.8%
3Y+194.0%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Nutriband Inc, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Total revenue	2.0	2.1	2.1	2.1	1.4	0.9
Cost of revenue	1.5	1.4	1.2	1.3	0.9	0.6
Gross profit	0.6	0.7	0.9	0.8	0.5	0.4
Selling, general & administrative expenses	7.0	4.3	3.8	3.9	4.0	3.0
Research & development	1.9	3.1	2.0	1.0	0.4	–
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	0	4.0	0.6	0.3	2.1	0.1
Other operating expenses	0	0	0	0	0	0
Operating income	−8.3	−10.7	−5.4	−4.5	−6.1	−2.7
Net interest income (expense)	0.1	0.2	−0.1	0	−0.1	−0.3
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0	0	0	0	0	0
Net income before taxes	−8.2	−10.5	−5.5	−4.5	−6.2	−2.9
Provision for taxes	0	0	0	0	0	0
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	−8.2	−10.5	−5.5	−4.5	−6.2	−2.9
Extraordinary items	–	–	–	–	–	–
Net income	−8.2	−10.5	−5.5	−4.5	−6.2	−2.9
EBIT, normalized	−8.3	−6.7	−4.9	−4.1	−3.9	−2.6
EBITDA, normalized	−8.1	−6.4	−4.6	−3.8	−3.6	−2.4
Basic EPS, normalized	−2.58	−0.99	–	−0.53	−0.81	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Nutriband Inc, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Assets
Cash & short-term investments	4.6	4.3	0.5	2.0	4.9	0.2
Receivables	0.1	0.1	0.1	0.1	0.1	0.1
Total inventory	0.1	0.2	0.2	0.2	0.1	0.1
Prepaid expenses	0.2	0.2	0.2	0.4	0.4	–
Other current assets	0	0	0	0	0	0
Total current assets	5.0	4.8	1.0	2.7	5.5	0.3
Property, plant & equipment	0.6	0.7	0.8	1.0	1.0	1.1
Goodwill	1.7	1.7	5.0	5.0	5.3	7.5
Intangibles	0.2	0.3	0.7	0.8	0.9	1.0
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	0	0	0	0	0	0
Total assets	7.5	7.5	7.5	9.5	12.7	9.9
Liabilities
Accounts payable	–	–	–	–	–	–
Payable/accrued	0.5	0.7	0.7	0.5	0.6	0.9
Accrued expenses	0	0	0	0	0	0
Short-term debt	0	0	0	0	0	1.4
Current portion of long-term debt	0.1	0.1	0.1	0	0	0.1
Other current liabilities	0.1	0.2	0.2	0.2	0.1	0.1
Total current liabilities	0.8	1.0	1.0	0.7	0.8	2.6
Long-term debt	0	0.1	0.1	0.1	0.1	0.2
Minority interest	–	–	–	–	–	–
Other liabilities	0	0	0	0	0	0
Total liabilities	0.9	1.0	1.1	0.9	0.9	2.8
Shareholders' equity
Preferred stock	0	0	0	0	0	–
Common stock	0	0	0	0	0	0.1
Additional paid-in capital	53.4	45.0	34.4	31.1	30.0	18.9
Retained earnings (accumulated deficit)	−46.7	−38.5	−28.0	−22.5	−18.0	−11.8
Treasury stock	−0.1	−0.1	0	0	−0.1	–
Other equity	0	0	0	0	0	0
Total equity	6.7	6.4	6.4	8.6	11.9	7.1
Total liabilities & shareholders' equity	7.5	7.5	7.5	9.5	12.7	9.9

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Nutriband Inc, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Operating activities
Net income	−8.2	−10.5	−5.5	−4.5	−6.2	−2.9
Depreciation, depletion & amortization	0.2	0.3	0.3	0.3	0.3	0.2
Deferred taxes	–	–	–	–	–	–
Non-cash items	2.8	5.5	1.4	1.4	3.6	2.4
Changes in working capital	0.1	0	0.2	−0.2	−0.5	0.1
Cash from operations	−5.1	−4.6	−3.5	−3.0	−2.8	−0.3
Investing activities
Capital expenditures	0	−0.1	−0.1	−0.1	−0.1	–
Other investing cash flows	0	0	0	0	0	0.1
Cash from investing	0	−0.1	−0.1	−0.1	−0.1	0.1
Financing activities
Financing cash flow items	–	–	–	–	0	0
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	5.4	8.5	2.1	0.2	7.6	0.4
Cash from financing	5.4	8.5	2.1	0.2	7.6	0.4
Foreign exchange effects	–	–	–	0	0	–
Net change in cash	0.3	3.8	−1.5	−2.9	4.7	0.1
Free cash flow	−5.1	−4.7	−3.6	−3.1	−2.9	−0.3

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.